With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Strive to empower public health with disinfection robotics solutions in post-pandemic era
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Subscribe To Our Newsletter & Stay Updated
